Suppressive effect of bacterial polysaccharides on BAFF system is responsible for their poor immunogenicity

Journal of Immunology

Volumn 186, Issue 4, 2011, Pages 2430-2443

  Kanswal, Sunita ^a   Katsenelson, Nora ^a   Allman, Windy ^a   Uslu, Kadriye ^a   Blake, Milan S ^a   Akkoyunlu, Mustafa ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(4 HYDROXY 3 NITROPHENYL)ACETYL FICOLL; ANTIGEN; APRIL PROTEIN; B CELL ACTIVATING FACTOR RECEPTOR; BACTERIAL POLYSACCHARIDE; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; GROUP B STREPTOCOCCUS SEROTYPE V; IMMUNOGLOBULIN; MENINGOCOCCAL TYPE C POLYSACCHARIDE; T CELL INDEPENDENT TYPE 2 ANTIGEN; TOLL LIKE RECEPTOR 9; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR; UNCLASSIFIED DRUG; VACCINE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; DOWN REGULATION; HUMAN; IMMUNOGENICITY; IMMUNOGLOBULIN PRODUCTION; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; BACTERIAL CAPSULES; BACTERIAL VACCINES; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; GROWTH INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED BALB C; NEISSERIA MENINGITIDIS, SEROGROUP C; NF-KAPPA B; POLYSACCHARIDES, BACTERIAL; SIGNAL TRANSDUCTION;

EID: 79951846194     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1002976     Document Type: Article

References (56)

1. Klein Klouwenberg, P., and L. Bont. 2008. Neonatal and infantile immune responses to encapsulated bacteria and conjugate vaccines. Clin. Dev. Immunol. 2008: 628963.
2. Kocabas, C., N. Katsenelson, S. Kanswal, M. N. Kennedy, X. Cui, M. S. Blake, D. M. Segal, and M. Akkoyunlu. 2007. Neisseria meningitidis type C capsular polysaccharide inhibits lipooligosaccharide-induced cell activation by binding to CD14. Cell. Microbiol. 9: 1297-1310.
3. Moxon, E. R., and J. S. Kroll. 1988. Type b capsular polysaccharide as a virulence factor of Haemophilus influenzae. Vaccine 6: 113-115.
4. Smith, H. 1977. Microbial surfaces in relation to pathogenicity. Bacteriol. Rev. 41: 475-500.
5. Wilson, J. W., M. J. Schurr, C. L. LeBlanc, R. Ramamurthy, K. L. Buchanan, and C. A. Nickerson. 2002. Mechanisms of bacterial pathogenicity. Postgrad. Med. J. 78: 216-224.
6. Ruegsegger, J. M., and M. Finland. 1935. The influence of dosage and route of injection on the antibody response of human subjects to the specific carbohydrate of the type Viii pneumococcus. J. Clin. Invest. 14: 833-836.
7. Weintraub, A. 2003. Immunology of bacterial polysaccharide antigens. Carbohydr. Res. 338: 2539-2547.
8. Mond, J. J., Q. Vos, A. Lees, and C. M. Snapper. 1995. T cell independent antigens. Curr. Opin. Immunol. 7: 349-354.
9. Lesinski, G. B., and M. A. Westerink. 2001. Vaccines against polysaccharide antigens. Curr. Drug Targets Infect. Disord. 1: 325-334.
10. Barrett, D. J., and E. M. Ayoub. 1986. IgG2 subclass restriction of antibody to pneumococcal polysaccharides. Clin. Exp. Immunol. 63: 127-134.
11. Moss, R. B., Y. P. Hsu, P. H. Van Eede, A. M. Van Leeuwen, N. J. Lewiston, and G. De Lange. 1987. Altered antibody isotype in cystic fibrosis: impaired natural antibody response to polysaccharide antigens. Pediatr. Res. 22: 708-713.
12. Siegrist, C. A. 2007. The challenges of vaccine responses in early life: selected examples. J. Comp. Pathol. 137(Suppl 1): S4-S9.
13. Adkins, B., C. Leclerc, and S. Marshall-Clarke. 2004. Neonatal adaptive immunity comes of age. Nat. Rev. Immunol. 4: 553-564.
14. Rijkers, G. T., E. A. Sanders, M. A. Breukels, and B. J. Zegers. 1998. Infant B cell responses to polysaccharide determinants. Vaccine 16: 1396-1400.
15. Haas, K. M., J. C. Poe, and T. F. Tedder. 2009. CD21/35 promotes protective immunity to Streptococcus pneumoniae through a complement-independent but CD19-dependent pathway that regulates PD-1 expression. J. Immunol. 183: 3661-3671.
16. von Bülow, G. U., J. M. van Deursen, and R. J. Bram. 2001. Regulation of the T-independent humoral response by TACI. Immunity 14: 573-582.
17. Mackay, F., and P. Schneider. 2009. Cracking the BAFF code. Nat. Rev. Immunol. 9: 491-502.
18. Sasaki, Y., S. Casola, J. L. Kutok, K. Rajewsky, and M. Schmidt-Supprian. 2004. TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology. J. Immunol. 173: 2245-2252. (Pubitemid 39063079)
19. Thompson, J. S., S. A. Bixler, F. Qian, K. Vora, M. L. Scott, T. G. Cachero, C. Hession, P. Schneider, I. D. Sizing, C. Mullen, et al. 2001. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 293: 2108-2111. (Pubitemid 32848062)
20. Castigli, E., S. A. Wilson, S. Scott, F. Dedeoglu, S. Xu, K. P. Lam, R. J. Bram, H. Jabara, and R. S. Geha. 2005. TACI and BAFF-R mediate isotype switching in B cells. J. Exp. Med. 201: 35-39.
21. Litinskiy, M. B., B. Nardelli, D. M. Hilbert, B. He, A. Schaffer, P. Casali, and A. Cerutti. 2002. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat. Immunol. 3: 822-829.
22. Kanswal, S., N. Katsenelson, A. Selvapandiyan, R. J. Bram, and M. Akkoyunlu. 2008. Deficient TACI expression on B lymphocytes of newborn mice leads to defective Ig secretion in response to BAFF or APRIL. J. Immunol. 181: 976-990.
23. Ozcan, E., L. Garibyan, J. J. Lee, R. J. Bram, K. P. Lam, and R. S. Geha. 2009. Transmembrane activator, calcium modulator, and cyclophilin ligand interactor drives plasma cell differentiation in LPS-activated B cells. J. Allergy Clin. Immunol. 123:1277-1286.e5.
24. Mantchev, G. T., C. S. Cortesão, M. Rebrovich, M. Cascalho, and R. J. Bram. 2007. TACI is required for efficient plasma cell differentiation in response to T-independent type 2 antigens. J. Immunol. 179: 2282-2288.
25. O'Connor, B. P., V. S. Raman, L. D. Erickson, W. J. Cook, L. K. Weaver, C. Ahonen, L. L. Lin, G. T. Mantchev, R. J. Bram, and R. J. Noelle. 2004. BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med. 199: 91-98.
26. Darce, J. R., B. K. Arendt, X. Wu, and D. F. Jelinek. 2007. Regulated expression of BAFF-binding receptors during human B cell differentiation. J. Immunol. 179: 7276-7286.
27. Yan, M., H. Wang, B. Chan, M. Roose-Girma, S. Erickson, T. Baker, D. Tumas, I. S. Grewal, and V. M. Dixit. 2001. Activation and accumulation of B cells in TACI-deficient mice. Nat. Immunol. 2: 638-643.
28. Katsenelson, N., S. Kanswal, M. Puig, H. Mostowski, D. Verthelyi, and M. Akkoyunlu. 2007. Synthetic CpG oligodeoxynucleotides augment BAFF- and APRIL-mediated immunoglobulin secretion. Eur. J. Immunol. 37: 1785-1795.
29. Mosier, D. E., B. M. Johnson, W. E. Paul, and P. R. McMaster. 1974. Cellular requirements for the primary in vitro antibody response to DNP-ficoll. J. Exp. Med. 139: 1354-1360.
30. Moore, P. A., O. Belvedere, A. Orr, K. Pieri, D. W. LaFleur, P. Feng, D. Soppet, M. Charters, R. Gentz, D. Parmelee, et al. 1999. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285: 260-263. (Pubitemid 29330000)
31. Schneider, P., F. MacKay, V. Steiner, K. Hofmann, J. L. Bodmer, N. Holler, C. Ambrose, P. Lawton, S. Bixler, H. Acha-Orbea, et al. 1999. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J. Exp. Med. 189: 1747-1756.
32. Yu, G., T. Boone, J. Delaney, N. Hawkins, M. Kelley, M. Ramakrishnan, S. McCabe, W. R. Qiu, M. Kornuc, X. Z. Xia, et al. 2000. APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity. Nat. Immunol. 1: 252-256.
33. Dillon, S. R., J. A. Gross, S. M. Ansell, and A. J. Novak. 2006. An APRIL to remember: novel TNF ligands as therapeutic targets. Nat. Rev. Drug Discov. 5: 235-246.
34. Claudio, E., K. Brown, S. Park, H. Wang, and U. Siebenlist. 2002. BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat. Immunol. 3: 958-965.
35. Kayagaki, N., M. Yan, D. Seshasayee, H. Wang, W. Lee, D. M. French, I. S. Grewal, A. G. Cochran, N. C. Gordon, J. Yin, et al. 2002. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity 17: 515-524. (Pubitemid 35223539)
36. Hatada, E. N., R. K. Do, A. Orlofsky, H. C. Liou, M. Prystowsky, I. C. MacLennan, J. Caamano, and S. Chen-Kiang. 2003. NF-kappa B1 p50 is required for BLyS attenuation of apoptosis but dispensable for processing of NFkappa B2 p100 to p52 in quiescent mature B cells. J. Immunol. 171: 761-768. (Pubitemid 36871386)
37. Gotschlich, E. C., I. Goldschneider, and M. S. Artenstein. 1969. Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J. Exp. Med. 129: 1367-1384.
38. Goldschneider, I., E. C. Gotschlich, and M. S. Artenstein. 1969. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129: 1307-1326.
39. Lai, Z., and J. R. Schreiber. 2009. Antigen processing of glycoconjugate vaccines; the polysaccharide portion of the pneumococcal CRM(197) conjugate vaccine co-localizes with MHC II on the antigen processing cell surface. Vaccine 27: 3137-3144.
40. Bhattacharjee, A. K., H. J. Jennings, C. P. Kenny, A. Martin, and I. C. Smith. 1975. Structural determination of the sialic acid polysaccharide antigens of Neisseria meningitidis serogroups B and C with carbon 13 nuclear magnetic resonance. J. Biol. Chem. 250: 1926-1932.
41. Wessels, M. R., J. L. DiFabio, V. J. Benedì, D. L. Kasper, F. Michon, J. R. Brisson, J. Jelínková, and H. J. Jennings. 1991. Structural determination and immunochemical characterization of the type V group B Streptococcus capsular polysaccharide. J. Biol. Chem. 266: 6714-6719.
42. Carlin, A. F., S. Uchiyama, Y. C. Chang, A. L. Lewis, V. Nizet, and A. Varki. 2009. Molecular mimicry of host sialylated glycans allows a bacterial pathogen to engage neutrophil Siglec-9 and dampen the innate immune response. Blood 113: 3333-3336.
43. Duong, B. H., H. Tian, T. Ota, G. Completo, S. Han, J. L. Vela, M. Ota, M. Kubitz, N. Bovin, J. C. Paulson, and D. Nemazee. 2010. Decoration of T-independent antigen with ligands for CD22 and Siglec-G can suppress immunity and induce B cell tolerance in vivo. J. Exp. Med. 207: 173-187.
44. Nitschke, L. 2009. CD22 and Siglec-G: B-cell inhibitory receptors with distinct functions. Immunol. Rev. 230: 128-143.
45. Pollard, A. J., K. P. Perrett, and P. C. Beverley. 2009. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat. Rev. Immunol. 9: 213-220.
46. Lees, A., F. Finkelman, J. K. Inman, K. Witherspoon, P. Johnson, J. Kennedy, and J. J. Mond. 1994. Enhanced immunogenicity of protein-dextran conjugates: I. Rapid stimulation of enhanced antibody responses to poorly immunogenic molecules. Vaccine 12: 1160-1166.
47. Daridon, C., P. Youinou, and J. O. Pers. 2008. BAFF, APRIL, TWE-PRIL: who's who? Autoimmun. Rev. 7: 267-271.
48. Chen, L., M. J. Ran, X. X. Shan, M. Cao, P. Cao, X. M. Yang, and S. Q. Zhang. 2009. BAFF enhances B-cell-mediated immune response and vaccine-protection against a very virulent IBDV in chickens. Vaccine 27: 1393-1399.
49. Tertilt, C., J. Joh, A. Krause, P. Chou, K. Schneeweiss, R. G. Crystal, and S. Worgall. 2009. Expression of B-cell activating factor enhances protective immunity of a vaccine against Pseudomonas aeruginosa. Infect. Immun. 77: 3044-3055.
50. Rodriguez, M. E., G. P. van den Dobbelsteen, L. A. Oomen, O. de Weers, L. van Buren, M. Beurret, J. T. Poolman, and P. Hoogerhout. 1998. Immunogenicity of Streptococcus pneumoniae type 6B and 14 polysaccharide-tetanus toxoid conjugates and the effect of uncoupled polysaccharide on the antigen-specific immune response. Vaccine 16: 1941-1949. (Pubitemid 28473940)
51. Peeters, C. C., A. M. Tenbergen-Meekes, J. T. Poolman, B. J. Zegers, and G. T. Rijkers. 1992. Immunogenicity of a Streptococcus pneumoniae type 4 polysaccharide - protein conjugate vaccine is decreased by admixture of high doses of free saccharide. Vaccine 10: 833-840.
52. von Hunolstein, C., R. Teloni, S. Mariotti, S. Recchia, G. Orefici, and R. Nisini. 2000. Synthetic oligodeoxynucleotide containing CpG motif induces an antipolysaccharide type 1-like immune response after immunization of mice with Haemophilus influenzae type b conjugate vaccine. Int. Immunol. 12: 295-303.
53. Kovarik, J., P. Bozzotti, C. Tougne, H. L. Davis, P. H. Lambert, A. M. Krieg, and C. A. Siegrist. 2001. Adjuvant effects of CpG oligodeoxynucleotides on responses against T-independent type 2 antigens. Immunology 102: 67-76.
54. Xia, R., Z. Han, Y. Zhou, S. Chen, B. Chen, M. Gu, A. Deng, R. Zhong, and H. Wen. 2010. BLyS and APRIL expression in peripheral blood mononuclear cells of cryptococcal meningitis patients and their clinical significance. Clin. Biochem. 43: 397-400.
55. Sundstrom, J. B., and R. Cherniak. 1992. The glucuronoxylomannan of Cryptococcus neoformans serotype A is a type 2 T-cell-independent antigen. Infect. Immun. 60: 4080-4087.
56. Zaragoza, O., M. L. Rodrigues, M. De Jesus, S. Frases, E. Dadachova, and A. Casadevall. 2009. The capsule of the fungal pathogen Cryptococcus neoformans. Adv. Appl. Microbiol. 68: 133-216.